Jame Abraham, Enterprise Chairman and Professor at the Department of Hematology and Medical Oncology at Cleveland Clinic, shared a post by FDA Oncology on X, adding:
“TDXd is moving to neoadjuvant and post neoadjuvant ( adjuvant) setting – more treatment options for patients with high risk her-2 positive breast cancer.”
Other articles featuring Jame Abraham on OncoDaily.
Quoting FDA Oncology‘s post:
FDA Approves T-DXd for Two Early HER2-Positive Breast Cancer Settings
